Short Interest in Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Expands By 15.2%

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) (TSE:CPH) saw a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 142,800 shares, an increase of 15.2% from the November 15th total of 124,000 shares. Based on an average trading volume of 31,500 shares, the short-interest ratio is presently 4.5 days.

Cipher Pharmaceuticals Trading Down 1.3 %

Cipher Pharmaceuticals stock traded down $0.13 during midday trading on Monday, reaching $9.88. 28,004 shares of the company were exchanged, compared to its average volume of 23,040. The firm’s 50-day simple moving average is $11.03 and its 200-day simple moving average is $9.70. Cipher Pharmaceuticals has a 1 year low of $4.14 and a 1 year high of $14.60.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.